Iovance Biotherapeutics Inc

Stock Chart, Company Information, and Scan Results

$3.13(as of Jul 22, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Iovance Biotherapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$3.13
Ticker SymbolIOVA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees838
CountyUSA
Market Cap$831.5M
EBIDTA-365.0M
10-Day Moving Average2.22
P/E Ratio-2.69
20-Day Moving Average1.98
Forward P/E Ratio0.00
50-Day Moving Average1.94
Earnings per Share-1.22
200-Day Moving Average5.39
Profit Margin-235.51%
RSI76.32
Shares Outstanding333.9M
ATR0.24
52-Week High12.51
Volume48,892,208
52-Week Low1.64
Most Recent Support Level1.70
Book Value767.9M
Most Recent Resistance Level2.50
P/B Ratio1.32
Upper Keltner2.52
P/S Ratio4.75
Lower Keltner1.44
Debt-to-Equity Ratio2.52
Next Earnings Date08/07/2025
Cash Surplus49.0M
Next Ex-Dividend DateUnknown

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Inc In Our Stock Scanner

example chart graphic
Date: Jul 23, 2025Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.